

Acute respiratory distress syndrome and acute kidney injury in critically ill patients: a scoping review protocol about the lung-kidney crosstalk

Francisco Z. Mattedi^{1*}, Heitor S. Ribeiro^{1*}, Geraldo F. Busatto², Carlos R. R. Carvalho³, and Emmanuel A. Burdmann¹ on behalf of the HCFMUSP COVID-19 Study Group

¹ LIM 12, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, BR.

² Departamento e Instituto de Psiquiatria, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, BR.

³ Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, BR.

* These authors contributed equally and share the first author position.

Corresponding author: Emmanuel A. Burdmann, MD, PhD. Laboratório de Investigação (LIM) 12, Serviço de Nefrologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Postal Code: 01246-903; Office Phone: +551130617343; Email: burdmann@usp.br.

Acute respiratory distress syndrome and acute kidney injury in critically ill patients: a scoping review protocol about the lung-kidney crosstalk

ABSTRACT

Introduction: Acute respiratory distress syndrome (ARDS) is a risk factor for several adverse clinical outcomes, including mortality. Acute kidney injury (AKI) is one of the most common extrapulmonary complications in ARDS. Despite the high incidence of AKI in patients with ARDS, the lung-kidney crosstalk is not yet fully understood.

Objective: This scoping review aims to describe the association between ARDS and AKI in critically ill patients.

Methods: We will follow the Joanna Briggs Institute methodology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews. Based on the Participants, Concept, and Context framework, we will include studies that investigated critically ill patients with ARDS (**Participants**), describe AKI-related outcomes (**Concept**), and were conducted in hospitals (**Context**). A comprehensive literature search will be performed using the MEDLINE, Embase, and LILACS databases without date or language restrictions from database inception until January 2024. Observational studies with retrospective, prospective, and case-control designs will be considered. Two independent reviewers will screen titles and abstracts and perform full-text reviews. Data extraction will be performed by the main reviewer and checked by a second one. Data on the diagnosis of ARDS and follow-up time for AKI-related outcomes will be extracted from the selected evidence. The quantitative results will be synthesized and presented in tables and figures along with a narrative summary.

Ethics and dissemination: There is no ethical approval requirement for this scoping review. On completion, the review will be published in a peer-reviewed academic journal and presented at a health conference.

Keywords: acute kidney injury; renal replacement therapy; respiratory distress syndrome; artificial respiration; critically ill

Abstract word count: 247

Total manuscript word count: 2084

BACKGROUND

Acute respiratory distress syndrome (ARDS) is responsible for 10.4% of admissions to the intensive care unit (ICU) and is a risk factor for several adverse clinical outcomes, including mortality ¹. Acute kidney injury (AKI) is one of the most common extrapulmonary complications in ARDS ^{2,3}. Liu et al. analyzed data from the ARDSNET trial and reported a 24% incidence of AKI in patients with ARDS, which was associated with an increase in mortality (58% vs 28% in patients without AKI) ⁴. McNicholas et al. found an AKI incidence of 39% (15% of mild/moderate cases and 24% of severe cases) in patients with ARDS in the LUNG SAFE study cohort. AKI was associated with high mortality in both the ICU and hospital settings, and the mortality rates varied according to the AKI severity (49.9% in the mild/moderate AKI group and 57.9% in the severe group, compared with 30.8% in the group without AKI). Patients with ARDS-associated AKI had a longer hospital stay and fewer days free from mechanical ventilation (MV) compared with patients without AKI ².

Despite the high incidence of AKI in patients with ARDS, the lung-kidney crosstalk is not yet fully understood. ARDS-associated AKI may be a consequence of the critical illness context and develop independently, contributing to a higher mortality risk. On the other hand, ARDS may act as an independent risk factor for the development of AKI, participating in its pathophysiology, as suggested by previous studies ^{3,4}. The lung-kidney crosstalk might occur in both directions, with acute lung injury (ALI) leading to AKI and vice versa. Even so, this crosstalk remains to be explored, and investigations of temporal association, the impact on kidney function recovery, persistence of kidney replacement therapy (KRT), and the progression to chronic kidney disease are lacking.

The possible mechanisms of the lung-kidney crosstalk are related to hemodynamic, neurohormonal, and inflammatory changes caused by a primary lung injury. In a cohort of patients with ARDS, increased levels of interleukin (IL)-6, soluble tumor necrosis factor receptors (sTNFR-I and -II), and plasminogen activator inhibitor-1 (PAI-1) were markedly associated with AKI development ⁴. Hypoxemia and hypercapnia are associated with increased renal vascular resistance ^{5,6}. Positive end-expiratory pressure (PEEP) during MV was related to a reduction in cardiac output, glomerular filtration rate (GFR), and renal blood flow, in addition to the activation of antidiuretic hormone and the renin-angiotensin-aldosterone system, promoting water retention ⁷.

Biotrauma induced by MV is associated with an increase in the levels of inflammatory markers, including IL-1-beta, IL-6, IL-8, and TNF-alpha, mainly in patients undergoing non-protective ventilation. There are some data showing an increased risk of AKI development after ARDS, regardless of the ventilation parameters used ^{8,9}. In a rabbit model of ALI, the animals were randomized to receive protective or conventional (non-protective) ventilation ¹⁰. The conventional ventilation group showed an increase in the levels of inflammatory markers and serum creatinine (sCr) and apoptosis compared with the protective ventilation group. In a similar model in pigs, infiltration of inflammatory cells in the kidney, heart, and liver was noted among animals undergoing conventional ventilation compared with the group receiving protective ventilation ¹¹.

Data on AKI after ARDS in the clinical setting are not consistent, and there is high heterogeneity in the definitions of ARDS and AKI. ARDS is mainly defined by the Berlin criteria ¹²; however, the American-European Consensus Conference (AECC)¹³ criteria is also used. For AKI, definitions based on the Kidney Disease: Improving Global Outcomes (KDIGO) 2012; Acute Kidney Injury Network; and Risk, Injury, Failure, Loss of Kidney Function, and End-stage Kidney Disease criteria and other adapted definitions have been used. Outcomes are also heterogeneous. The most frequently evaluated outcomes in patients with ARDS are the incidence of AKI and mortality. However, the time to develop AKI, incidence of KRT, recovery of renal function, and progression to CKD are not reported in most articles. Hence, the impact of ARDS as a risk factor for AKI remains poorly evaluated.

Darmon et al. demonstrated that 44.3% of patients with ARDS admitted to the ICU developed AKI compared with 27.4% of patients without ARDS. Mortality was also higher in the ARDS-AKI group than in the ARDS group without AKI (27.6% vs 8.1%). In this study, ARDS was identified as an independent risk factor for AKI (OR, 11.01; 95% CI, 6.83 to 17.73) ³. A Brazilian study that prospectively evaluated 100 patients admitted to the ICU with pulmonary disease who subsequently developed ARDS showed that a partial pressure of oxygen in arterial blood/fraction of inspiratory oxygen concentration ($\text{PaO}_2/\text{FIO}_2$, P/F ratio) lower than 200 mmHg on admission was independently associated with subsequent AKI development ¹⁴. Clemens et al. evaluated 830 patients admitted to the USAISR Burn Center and showed an AKI incidence of 27% in patients who developed ARDS. In univariate analysis, ARDS was identified as an independent risk factor for AKI; however, this result was not confirmed in the multivariate analysis ¹⁵. In a retrospective cohort of patients hospitalized with coronavirus

disease 2019 (COVID-19), the incidence of AKI was higher in the group with ARDS/MV (89.7% vs. 21.7% in non-ventilated patients)¹⁶. In a recent meta-analysis, a higher incidence of AKI and the need for KRT was found in COVID-19 cohorts with ARDS compared with those without it¹⁷. ARDS was not described as an independent risk factor for AKI in the KDIGO 2012 guidelines and the KDIGO Controversies Conference on Acute Kidney Injury in 2019^{18,19}.

A systematic review and meta-analysis of 17 studies evaluating the incidence and clinical outcomes in patients who developed AKI after ARDS was recently published²⁰. Therein, the pooled incidence rate of AKI after ARDS was 39% (95% CI, 32 to 46%). Furthermore, the mortality rate was higher in the patients who developed AKI after ARDS. ARDS was an independent risk factor for the development of AKI in only two studies. Although these results indicate a possible association between ARDS and AKI, prospective cohort studies specifically designed to answer this question are needed to improve the understanding of the ARDS-AKI association.

Considering the heterogeneity of clinical data regarding lung-kidney crosstalk, we decided to conduct this scoping review to evaluate the evidence on the relationship between these two clinical entities and the gaps present in the literature.

Review question

How is the association between ARDS and AKI described in the literature?

ELIGIBILITY CRITERIA

Eligibility criteria based on the PCC framework are shown in **Table 1** and described below in detail.

Table 1. Participants, Concept, Context (PCC) framework.

	Definition
Participants	Adults with acute lung injury/ARDS
Concept	AKI incidence, AKI stages, need/use for/of KRT, and kidney function recovery
Context	ICU, ward, emergency room, and community settings

AKI, acute kidney injury; ICU, intensive care unit; KRT, kidney replacement therapy.

Participants

In this scoping review, adults (aged ≥ 18 years) who were in the ICU, ward, or emergency room with ALI/ARDS will be considered. The last group will be diagnosed based

on the most prominent guidelines, such as the Berlin criteria¹² and the AECC criteria¹³. However, studies that applied other definitions will also be considered.

Concept

We will use sources pertaining to the assessment of patients with ALI/ARDS, which also included the assessment of kidney function (sCr and/or urinary output), diagnosis of AKI (stages of AKI), time to the diagnosis, description of the need for or use of KRT, and kidney function recovery. AKI will be defined based on the KDIGO¹⁸, AKIN²¹, and RIFLE²² criteria or the use of KRT. However, studies that adopted other AKI definitions will also be considered.

Context

Evidence from investigations of ARDS and kidney function conducted in the ICU, ward, emergency room, and community settings will be considered.

Types of Sources

All types of observational study designs (e.g., retrospective, prospective, and case-control studies) will be considered. Reviews, commentaries, and letters to the editor will not be included.

METHODS

The proposed scoping review will be conducted following the Joanna Briggs Institute (JBI) methodology for scoping reviews²³ and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR)²⁴.

Search Strategy

We designed a search strategy to mainly locate published evidence by a peer-review process. A preliminary search on MEDLINE was undertaken to identify relevant articles on the topic. The text words contained in the titles and abstracts of the relevant articles and the index terms used to describe the articles were used to develop a full search strategy for the MEDLINE, EMBASE, and LILACS databases. The search strategy, including all identified keywords and index terms, has been adapted for each database and/or information source (see **Appendix 1**). The databases were searched from inception to January 2024. The reference lists of all the included sources of evidence will be screened for additional studies;

no language restrictions will be applied. Sources of unpublished studies and gray literature to be searched include Google Scholar and Google up to the fifth search page.

Source of evidence selection

All identified citations were collated and uploaded into the Covidence systematic review software (Veritas Health Innovation, Melbourne, AU), where duplicates were removed for the screening process. Following a pilot test, the titles and abstracts will be screened by two independent reviewers (FZM and HSR) for assessment against the inclusion criteria. The full text of the selected evidence will be assessed in detail by the same independent reviewers. Reasons for the exclusion of sources of evidence in full texts that do not meet the inclusion criteria will be recorded. Any disagreements between the reviewers at each stage of the selection process will be resolved through discussion or by consulting an additional reviewer (EAB). The results of the search and the study inclusion process will be reported in full in the final scoping review and presented in the PRISMA-ScR flow diagram.

Data extraction

Data will be extracted from the studies included in the scoping review by the main reviewer (FZM) and checked by a second reviewer (HSR) by using a data extraction spreadsheet adapted from the JBI Manual for Evidence Synthesis²⁵. The extracted data will include specific details about MV, diagnosis of ARDS, kidney function, development of AKI, and other items. Additional general information will be extracted, including the author(s), year of publication, and country. A draft extraction form is provided (see **Appendix 2**). The draft data extraction tool will be modified and revised as necessary during the process of data extraction. Any disagreements between the reviewers will be resolved through discussion or by consulting an additional reviewer (EAB). If necessary, the authors of the studies will be contacted to request missing or additional data.

Quality assessment

Methodological quality assessment of the included studies will be conducted independently by two reviewers (FZM and HSR) by using the JBI Critical Appraisal Checklist²⁶. The JBI tool consists of nine items with four possible responses (*Yes, No, Unclear, or Not*

applicable). The greater the number of *Yes* answers, the better the quality of the study. We will dichotomize the studies high quality (below the median) and low quality (above the median) for further analysis. Disagreements will be resolved through consensus or by consulting a third reviewer (EAB).

Data analysis and presentation

The findings from the scoping review will be reported per the PRISMA-ScR guideline²⁴. Data will be synthesized and presented in tables and figures along with a narrative summary. Statistical analysis will be performed using the Statistical Package for the Social Sciences (version 29.0, IBM Corp., Armonk, NY, USA).

Patient and public involvement

There will be no patient and public involvement during the review process; however, results will be shared and disseminated throughout an extended network within the Hospital das Clínicas da Universidade de São Paulo (HCFMUSP), which includes patients, their relatives, stakeholders, and others.

Ethics and dissemination

There is no requirement for ethical approval for this scoping review. On completion, it will be published in a peer-reviewed academic journal and presented at a conference.

Acknowledgments

We would like to thank Editage (www.editage.com) for English language editing.

Funding

This study receives funding from the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), grant #22/01769-5. EAB receives a research grant (*Bolsa de Produtividade em Pesquisa*, 304743/2017-8) from The National Council for Scientific and Technological Development (CNPq).

Availability of data and materials

The datasets to be analyzed during the current study will be available from the corresponding author upon reasonable request.

Authors' contributions

FZM, HSR, and EAB conceived and designed the study. FZM wrote the first draft. HSR, GFB, CRRC, and EAB critically reviewed the manuscript. All authors read and approved the final version.

Conflict of interest

The authors declare that they have no competing interests.

REFERENCES

1. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA - J Am Med Assoc.* 2016;315(8):788-800. doi:10.1001/jama.2016.0291
2. McNicholas BA, Rezoagli E, Pham T, et al. Impact of early acute kidney injury on management and outcome in patients with acute respiratory distress syndrome: A secondary analysis of a multicenter observational study. *Crit Care Med.* 2019;47(9):1216-1225. doi:10.1097/CCM.0000000000003832
3. Darmon M, Clec'h C, Adrie C, et al. Acute respiratory distress syndrome and risk of AKI among critically ill patients. *Clin J Am Soc Nephrol.* 2014;9(8):1347-1353. doi:10.2215/CJN.08300813
4. Liu KD, Glidden D V., Eisner MD, et al. Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury. *Crit Care Med.* 2007;35(12):2755-2761. doi:10.1097/01.CCM.0000291649.72238.6D
5. Darmon M, Schortgen F, Leon R, et al. Impact of mild hypoxemia on renal function and renal resistive index during mechanical ventilation. *Intensive Care Med.* 2009;35(6):1031-1038. doi:10.1007/s00134-008-1372-5
6. Sharkey RA, Mulloy EMT, Long M, O'Neill SJ. The effect of continuous positive airway pressure (CPAP) on renal vascular resistance: The influence of renal denervation. *Crit Care.* 1999;3(1):33-37. doi:10.1186/cc304
7. Annat G, Viale JP, Xuan BB, et al. Effect of PEEP Ventilation on Renal Function, Plasma Renin, Aldosterone, Neurophysins and Urinary ADH, and Prostaglandins.

- Anesthesiology*. 1983;58(2):136-141. doi:10.1097/00000542-198302000-00006
8. Ranieri VM, Suter PM, Tortorella C, et al. Effect of Mechanical Ventilation on Inflammatory Mediators in Patients With Acute Respiratory Distress Syndrome. *JAMA*. 1999;282(1):54. doi:10.1001/jama.282.1.54
 9. van den Akker JPC, Egal M, Groeneveld JAB. Invasive mechanical ventilation as a risk factor for acute kidney injury in the critically ill: A systematic review and meta-analysis. *Crit Care*. 2013;17(3). doi:10.1186/cc12743
 10. Imai Y, Perrot M De, Fischer S, et al. Injurious Mechanical Ventilation and End-Organ Epithelial Cell Apoptosis and Organ Dysfunction in an Experimental Model of Acute Respiratory Distress Syndrome. *Jama*. 2003;289(16):2104-2112.
 11. Heuer JF, Sauter P, Pelosi P, et al. Effects of pulmonary acid aspiration on the lungs and extra-pulmonary organs: A randomized study in pigs. *Crit Care*. 2012;16(2):R35. doi:10.1186/cc11214
 12. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: The Berlin definition. *Jama*. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669
 13. Bernard GR, Artigas A, Brigham KL, et al. Definitions , Mechanisms , Relevant Outcomes , and Clinical Trial Coordination. *Crit Care Med*. 1994;149:818-824.
 14. De Abreu KLS, Da Silva GB, Muniz TD, et al. Acute kidney injury in critically ill patients with lung disease: Kidney-lung crosstalk. *Rev Bras Ter Intensiva*. 2013;25(2):130-136. doi:10.5935/0103-507X.20130024
 15. Clemens MS, Stewart IJ, Sosnov JA, et al. Reciprocal Risk of Acute Kidney Injury and Acute Respiratory Distress Syndrome in Critically Ill Burn Patients. *Crit Care Med*. 2016;44(10):e915-e922. doi:10.1097/CCM.0000000000001812
 16. Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. *Kidney Int*. 2020;98(1):209-218. doi:10.1016/j.kint.2020.05.006
 17. Alenezi FK, Almeshari MA, Mahida R, Bangash MN, Thickett DR, Patel JM. Incidence and risk factors of acute kidney injury in COVID-19 patients with and without acute respiratory distress syndrome (ARDS) during the first wave of COVID-19: a systematic review and Meta-Analysis. *Ren Fail*. 2021;43(1):1621-1633. doi:10.1080/0886022X.2021.2011747
 18. Work Group Membership. *Kidney Int Suppl*. 2012;2(1):2. doi:10.1038/kisup.2012.2
 19. Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. *Kidney Int*. 2020;98(2):294-309. doi:10.1016/j.kint.2020.04.020
 20. Charkviani M, Truong HH, Nikravangolsefid N, et al. Temporal Relationship and Clinical

Outcomes of Acute Kidney Injury Following Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. *Crit Care Explor.* 2024;6(2). doi:10.1097/CCE.0000000000001054

21. Mehta RL, Kellum JA, Shah S V., et al. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. *Crit Care.* 2007;11(2):1-8. doi:10.1186/cc5713
22. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care.* 2004;8(4). doi:10.1186/cc2872
23. Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. *JBI Evid Synth.* 2020;18(10):2119-2126. doi:10.11124/JBIES-20-00167
24. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Ann Intern Med.* 2018;169(7):467-473. doi:10.7326/M18-0850
25. Peters MDJ, Godfrey C, Mcinerney P, Munn Z, Tricco AC, Khalil H. Chapter 11: Scoping reviews (2020 version). In: Aromataris E, Munn Z (Editors). *JBI Man Evid Synth.* 2020;(January):12-13. <https://synthesismanual.jbi.global>
26. Munn Z, MCLinSc SM, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc.* 2015;13(3):147-153. doi:10.1097/XEB.0000000000000054

Appendix I: Search strategy

MEDLINE – 352 references (18th January 2024)

#1 "Respiratory Distress Syndrome"[MeSH Terms] OR "Respiratory Insufficiency"[MeSH Terms] OR "respiration, artificial"[MeSH Terms] OR "Acute Lung Injury"[MeSH Terms] OR "Acute Chest Syndrome"[MeSH Terms]

#2 "Acute Kidney Injury"[MeSH Terms] OR "AKI"[All Fields] OR "AKF"[All Fields]

#3 "Intensive Care Units"[MeSH Terms] OR "Emergency Medical Services"[MeSH Terms] OR "Community Health Services"[MeSH Terms] OR "emergency service, hospital"[MeSH Terms] OR "Critical Care"[MeSH Terms]

#4 #1 AND #2 AND #3

#5 NOT animal*

#6 #4 AND #5

#7 NOT "child*" [All Fields] OR "infant*" [All Fields] OR "pediatric*" [All Fields]

#8 #6 AND #7

Embase – 2548 references (18th January 2024)

#1 'adult respiratory distress syndrome' OR 'acute lung injury' OR 'invasive ventilation' OR 'noninvasive ventilation'

#2 acute AND kidney AND injury

#3 'acute kidney failure' OR AKI OR AKF

#4 #2 OR #3

#5 'intensive care unit' OR 'emergency ward' OR 'community care'

#6 emergency AND care AND unit

#7 critical AND care AND unit

#8 #5 OR #6 OR #7

#9 #1 AND #4 AND #8

#10 NOT animal*

#11 #9 AND #10

#12 NOT child* NOT infant* NOT pediatric*

#13 #11 AND #12

LILACS – 43 references (18th January 2024)

Síndrome do Desconforto Respiratório OR Síndrome de Dificultad Respiratoria OR acute respiratory distress syndrome AND Injúria Renal Aguda OR Lesión Renal Aguda OR acute kidney injury

Appendix II: Draft extraction

Characteristics											
Author	Year	Country	Region	Study design	Sample characteristic	Sample	Men	Woman	Age (years)	AKI incidence in ARDS patients	Severity tool

No ARDS	ARDS	Diagnostic criteria for ARDS	ARDS definition	Mild - P/F 200-300	Moderate - P/F 100-200	Severe - P/F < 100

AKI Criteria	AKI biomarker	AKI definition	AKI diagnosis (time)	AKI with mild ARDS	AKI with moderate ARDS	AKI with severe ARDS	AKI 1 (risk)	AKI 2 (injury)	AKI 3 (failure)	Risk factors

Outcomes					
ICU length of stay	Hospital length of stay	ICU mortality	Hospital Mortality	AKI recovery	Dialysis